PDCD1 and neoplasm: Next, we focused on Y1.7LI and delayed treatment initiation until day 7 post-transplant, a time point at which anti-CTLA-4, anti-PD-1, anti-CTLA-4 plus anti-PD-1, or neoAg SLP vax still induced tumor rejection in a majority of mice (Figure 1D).